D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats

L. Debeljuk, I. Torres-Aleman, Andrew V Schally

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The effect of a potent agonistic LHRH analog D-Trp-6-LHRH on the hyperprolactinemia induced by haloperidol was tested in intact and ovariectomized female rats. The administration of D-Trp-6-LHRH at two dose levels (5 and 50 μg/day) for 20 days blocked the increase in serum PRL induced by haloperidol in intact as well as ovariectomized rats. The pituitary PRL concentration was also decreased by the administration of the analog in intact, but not ovariectomized, rats. Serum LH levels were significantly increased and the pituitary LH concentration was reduced by D-Trp-6-LHRH in intact rats. In ovariectomized rats, D-Trp-6-LHRH decreased serum as well as pituitary LH levels compared with levels in control rats. Another in vivo model to induced hyperprolactinemia consisted of grafting anterior pituitary glands under the kidney capsule in intact female rats. The administration of D-Trp-6-LHRH for 20 days (50 μg/day, sc) to rats bearing pituitary grafts blocked the hyperprolactinemia observed in similar animals injected with the vehicle only. Serum LH levels were increased after the administration of D-Trp-6-LHRH, whereas pituitary LH concentrations were significantly decreased in the rats treated with the analog. These results demonstrate that the LHRh agonist D-Trp-6-LHRH can counteract the hyperprolactinemic effect of haloperidol, and that this effect is not mediated by suppression of ovarian estrogens. The treatment with the analog blocked the hypersecretion of PRL by pituitary grafts, suggesting a direct effect of the analog on the pituitary gland to modulate PRL secretion.

Original languageEnglish
Pages (from-to)2227-2231
Number of pages5
JournalEndocrinology
Volume116
Issue number6
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Hyperprolactinemia
Gonadotropin-Releasing Hormone
Haloperidol
Serum
Transplants
Anterior Pituitary Gland
Pituitary Gland
Capsules
Estrogens
Kidney

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats. / Debeljuk, L.; Torres-Aleman, I.; Schally, Andrew V.

In: Endocrinology, Vol. 116, No. 6, 01.01.1985, p. 2227-2231.

Research output: Contribution to journalArticle

Debeljuk, L. ; Torres-Aleman, I. ; Schally, Andrew V. / D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats. In: Endocrinology. 1985 ; Vol. 116, No. 6. pp. 2227-2231.
@article{9ca11ee1e184440ca1ba915e505aa8b2,
title = "D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats",
abstract = "The effect of a potent agonistic LHRH analog D-Trp-6-LHRH on the hyperprolactinemia induced by haloperidol was tested in intact and ovariectomized female rats. The administration of D-Trp-6-LHRH at two dose levels (5 and 50 μg/day) for 20 days blocked the increase in serum PRL induced by haloperidol in intact as well as ovariectomized rats. The pituitary PRL concentration was also decreased by the administration of the analog in intact, but not ovariectomized, rats. Serum LH levels were significantly increased and the pituitary LH concentration was reduced by D-Trp-6-LHRH in intact rats. In ovariectomized rats, D-Trp-6-LHRH decreased serum as well as pituitary LH levels compared with levels in control rats. Another in vivo model to induced hyperprolactinemia consisted of grafting anterior pituitary glands under the kidney capsule in intact female rats. The administration of D-Trp-6-LHRH for 20 days (50 μg/day, sc) to rats bearing pituitary grafts blocked the hyperprolactinemia observed in similar animals injected with the vehicle only. Serum LH levels were increased after the administration of D-Trp-6-LHRH, whereas pituitary LH concentrations were significantly decreased in the rats treated with the analog. These results demonstrate that the LHRh agonist D-Trp-6-LHRH can counteract the hyperprolactinemic effect of haloperidol, and that this effect is not mediated by suppression of ovarian estrogens. The treatment with the analog blocked the hypersecretion of PRL by pituitary grafts, suggesting a direct effect of the analog on the pituitary gland to modulate PRL secretion.",
author = "L. Debeljuk and I. Torres-Aleman and Schally, {Andrew V}",
year = "1985",
month = "1",
day = "1",
language = "English",
volume = "116",
pages = "2227--2231",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats

AU - Debeljuk, L.

AU - Torres-Aleman, I.

AU - Schally, Andrew V

PY - 1985/1/1

Y1 - 1985/1/1

N2 - The effect of a potent agonistic LHRH analog D-Trp-6-LHRH on the hyperprolactinemia induced by haloperidol was tested in intact and ovariectomized female rats. The administration of D-Trp-6-LHRH at two dose levels (5 and 50 μg/day) for 20 days blocked the increase in serum PRL induced by haloperidol in intact as well as ovariectomized rats. The pituitary PRL concentration was also decreased by the administration of the analog in intact, but not ovariectomized, rats. Serum LH levels were significantly increased and the pituitary LH concentration was reduced by D-Trp-6-LHRH in intact rats. In ovariectomized rats, D-Trp-6-LHRH decreased serum as well as pituitary LH levels compared with levels in control rats. Another in vivo model to induced hyperprolactinemia consisted of grafting anterior pituitary glands under the kidney capsule in intact female rats. The administration of D-Trp-6-LHRH for 20 days (50 μg/day, sc) to rats bearing pituitary grafts blocked the hyperprolactinemia observed in similar animals injected with the vehicle only. Serum LH levels were increased after the administration of D-Trp-6-LHRH, whereas pituitary LH concentrations were significantly decreased in the rats treated with the analog. These results demonstrate that the LHRh agonist D-Trp-6-LHRH can counteract the hyperprolactinemic effect of haloperidol, and that this effect is not mediated by suppression of ovarian estrogens. The treatment with the analog blocked the hypersecretion of PRL by pituitary grafts, suggesting a direct effect of the analog on the pituitary gland to modulate PRL secretion.

AB - The effect of a potent agonistic LHRH analog D-Trp-6-LHRH on the hyperprolactinemia induced by haloperidol was tested in intact and ovariectomized female rats. The administration of D-Trp-6-LHRH at two dose levels (5 and 50 μg/day) for 20 days blocked the increase in serum PRL induced by haloperidol in intact as well as ovariectomized rats. The pituitary PRL concentration was also decreased by the administration of the analog in intact, but not ovariectomized, rats. Serum LH levels were significantly increased and the pituitary LH concentration was reduced by D-Trp-6-LHRH in intact rats. In ovariectomized rats, D-Trp-6-LHRH decreased serum as well as pituitary LH levels compared with levels in control rats. Another in vivo model to induced hyperprolactinemia consisted of grafting anterior pituitary glands under the kidney capsule in intact female rats. The administration of D-Trp-6-LHRH for 20 days (50 μg/day, sc) to rats bearing pituitary grafts blocked the hyperprolactinemia observed in similar animals injected with the vehicle only. Serum LH levels were increased after the administration of D-Trp-6-LHRH, whereas pituitary LH concentrations were significantly decreased in the rats treated with the analog. These results demonstrate that the LHRh agonist D-Trp-6-LHRH can counteract the hyperprolactinemic effect of haloperidol, and that this effect is not mediated by suppression of ovarian estrogens. The treatment with the analog blocked the hypersecretion of PRL by pituitary grafts, suggesting a direct effect of the analog on the pituitary gland to modulate PRL secretion.

UR - http://www.scopus.com/inward/record.url?scp=0021978413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021978413&partnerID=8YFLogxK

M3 - Article

C2 - 3158510

AN - SCOPUS:0021978413

VL - 116

SP - 2227

EP - 2231

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -